Tyrosine kinase inhibitors after progression on atezolizumab-bevacizumab in advanced hepatocellular carcinoma: A systematic review and meta-analysis

Table 2 Adverse events, %

Adverse event	Any grade	95%CI (any grade)	I2 (any grade)	≥ Grade 3 %	95%CI (≥ grade 3)	I2 (≥ 3)
AST/ALT elevation	42	-25 to 100	96.4	9	-10 to 29	67.5
Bilirubin elevation	38	12-65	0.00	4	-6 to 13	0.00
Thrombocytopenia	25	-15 to 65	97.6	3	0-6	0.00
Diarrhea	21	11-31	74.7	2	0-4	0.00
Anorexia	38	27-49	44.9	8	4-11	0.01
Proteinuria	30	18-42	55.3	15	10-20	0.00
Fatigue	52	39-65	76.42	6	3-9	0.01
Hypertension	18	7-29	85.32	3	1-6	0.05
Nausea	8	-7 to 22	72.65	4	-6 to 13	0.00
Anemia	54	27-81	0.00	4	-6 to 13	0.00
Hand-foot syndrome	34	21-47	80.6	3	1-5	0.01
Hypothyroidism	25	14-36	26.5	3	-1 to 6	0.03
Neutropenia	31	6-56	0.00	4	-6 to 13	0.00
Vomiting	5	1-10	0.01	2	-1 to 5	0.00
Gastrointestinal bleeding	1	-1 to 3	0.00	1	-1 to 3	0.00
Fever	12	2-23	0.01	2	-2 to 7	0.01
Non-gastrointestinal bleeding	12	2-23	0.01	3	-2 to 9	0.03
Liver failure	6	0-13	52.93	1	-1 to 3	0.00
Acute kidney injury	5	-6 to 15	64.90	1	-1 to 3	0.03
Abdominal pain	1	-1 to 3	0.01	1	-1 to 3	0.01
Hoarseness	6	-2 to 13	0.00	2	-2 to 7	0.01

CI: Confidence interval.